
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is a clinical-stage biotechnology company that has demonstrated a successful shift in focus to royalty-bearing assets and strategic partnerships, while also continuing to develop and test their promising drugs for autoimmune and inflammatory diseases. Their recent legal disputes with GSK/Tesaro may impact their future, but the potential revenue and growth from their assets and collaborations make AnaptysBio an attractive investment opportunity. With successful clinical trials and promising results, AnaptysBio has a positive outlook for future profitability and shareholder value.
Bears say
AnaptysBio is facing several challenges, including an ongoing lawsuit with GSK and potential risks that Jemperli royalties could go away. Despite the potential for revenue from Jemperli and other antibody candidates in clinical development, the overall financial health of the company may be hindered by its low operational expenses and dependence on royalty revenue streams. Additionally, with the completion of the spin-off of First Tracks Biotherapeutics, AnaptysBio may face difficulties in managing its clinical development programs and mitigating operating expenses. This, combined with the uncertain outcomes of its various clinical trials, leads to a negative outlook on the stock.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares